Vifor blasts FDA's 'reckless' renaming of 4 drugs under the same molecule moniker
Outside of the FDA’s decision to add four-letter, meaningless suffixes on the end of nonproprietary names for biologics, the naming of pharmaceuticals has not been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
